Biocardia Inc (BCDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $12.58M
Last updated: Nov 17, 2026 at 11:04 AM ET
Biocardia Inc (BCDA) Earnings: Report Dates and Results
Biocardia (BCDA) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Biocardia reported EPS of -$0.12, above the -$0.15 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BCDA has an expected report date of Mar 22, 2027.
BCDA Earnings Call
The latest BCDA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 29 quarters below that had an estimate, BCDA beat 19, missed 9 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2024, when EPS landed 780.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.12 | -$0.15 | -$0.15 - -$0.15 | +20.00% | Beat | N/A | 1 | 1 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.13 | -$0.19 | -$0.19 - -$0.19 | +31.58% | Beat | N/A | 1 | 0 up, 1 down | Aug 12, 2026 | N/A |
| Mar 31, 2026 | -$0.21 | -$0.17 | -$0.17 - -$0.17 | -23.53% | Miss | N/A | 1 | 0 up, 0 down | May 15, 2026 | N/A |
| Dec 31, 2025 | -$0.06 | -$0.20 | -$0.20 - -$0.20 | +70.00% | Beat | N/A | 1 | 1 up, 0 down | Mar 24, 2026 | N/A |
| Sep 30, 2025 | -$0.24 | -$0.25 | -$0.25 - -$0.25 | +4.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 12, 2025 | N/A |
| Jun 30, 2025 | -$0.40 | -$0.50 | N/A | +20.00% | Beat | N/A | N/A | 0 up, 0 down | Aug 11, 2025 | N/A |
| Mar 31, 2025 | -$0.59 | -$0.39 | N/A | -51.28% | Miss | N/A | N/A | 0 up, 0 down | May 14, 2025 | N/A |
| Dec 31, 2024 | -$0.25 | -$0.87 | -$0.87 - -$0.87 | +71.26% | Beat | N/A | 1 | 1 up, 0 down | Mar 26, 2025 | N/A |
| Sep 30, 2024 | -$0.61 | -$1.19 | N/A | +48.74% | Beat | N/A | N/A | N/A | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$0.88 | -$0.10 | N/A | -780.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 13, 2024 | N/A |
| Mar 31, 2024 | -$0.09 | -$0.20 | N/A | +54.90% | Beat | N/A | N/A | 0 up, 0 down | May 14, 2024 | $55000 |
| Dec 31, 2023 | -$1.35 | -$1.50 | -$1.80 - -$1.50 | +10.00% | Beat | N/A | 2 | 0 up, 0 down | Mar 27, 2024 | $13000 |
| Sep 30, 2023 | -$1.80 | -$1.65 | -$1.95 - -$1.65 | -9.09% | Miss | N/A | 2 | 0 up, 0 down | Nov 8, 2023 | $357000 |
| Jun 30, 2023 | -$2.55 | -$2.55 | -$2.55 - -$1.95 | 0.00% | In line | N/A | 3 | 0 up, 1 down | Aug 9, 2023 | $43000 |
| Mar 31, 2023 | -$2.55 | -$1.95 | -$3.30 - -$1.95 | -30.77% | Miss | N/A | 3 | 0 up, 0 down | May 10, 2023 | $64000 |
| Dec 31, 2022 | -$0.16 | -$0.18 | -$0.22 - -$0.13 | +11.11% | Beat | N/A | 3 | 0 up, 0 down | Mar 29, 2023 | $106000 |
| Sep 30, 2022 | -$2.55 | -$3.15 | -$3.75 - -$3.15 | +19.05% | Beat | N/A | 4 | 0 up, 0 down | Nov 9, 2022 | $212000 |
| Jun 30, 2022 | -$2.10 | -$6.30 | -$6.30 - -$2.70 | +66.67% | Beat | N/A | 5 | 0 up, 0 down | Aug 10, 2022 | $974000 |
| Mar 31, 2022 | -$2.85 | -$2.40 | N/A | -18.75% | Miss | N/A | 3 | 0 up, 0 down | May 11, 2022 | $60000 |
| Dec 31, 2021 | -$0.20 | -$0.21 | -$0.25 - -$0.12 | +4.76% | Beat | N/A | 4 | 0 up, 0 down | Mar 29, 2022 | $79000 |
| Sep 30, 2021 | -$2.40 | -$4.20 | -$4.20 - -$2.85 | +42.86% | Beat | N/A | 4 | 0 up, 0 down | Nov 10, 2021 | $821000 |
| Jun 30, 2021 | -$3.00 | -$3.45 | -$3.45 - -$2.70 | +13.04% | Beat | N/A | 3 | N/A | Aug 12, 2021 | $69000 |
| Mar 31, 2021 | -$0.18 | -$0.24 | -$0.28 - -$0.21 | +25.00% | Beat | N/A | 2 | N/A | May 13, 2021 | $46000 |
| Dec 31, 2020 | -$3.05 | -$4.65 | -$4.65 - -$4.20 | +34.41% | Beat | N/A | 3 | N/A | Mar 30, 2021 | $46000 |
| Sep 30, 2020 | -$4.50 | -$4.35 | -$4.35 - -$4.05 | -3.45% | Miss | N/A | 4 | N/A | Nov 10, 2020 | $34000 |
| Jun 30, 2020 | -$6.90 | -$6.00 | N/A | -15.00% | Miss | N/A | N/A | N/A | Aug 13, 2020 | $27000 |
| Mar 31, 2020 | -$7.20 | -$8.40 | N/A | +14.29% | Beat | N/A | 1 | N/A | Apr 9, 2020 | $38000 |
| Dec 31, 2019 | -$0.48 | -$0.51 | -$0.56 - -$0.46 | +5.88% | Beat | N/A | 2 | N/A | Dec 31, 2019 | $214000 |
| Sep 30, 2019 | -$9.45 | -$8.70 | N/A | -8.62% | Miss | N/A | N/A | N/A | Nov 19, 2019 | $194000 |
| Jun 30, 2019 | -$0.77 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 21, 2019 | $86000 |
| Mar 31, 2019 | -$0.85 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 2, 2019 | $216000 |
| Dec 31, 2018 | -$0.85 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 22, 2019 | $103000 |
| Sep 30, 2018 | -$0.81 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 8, 2018 | $84000 |
| Jun 30, 2018 | -$0.72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 9, 2018 | $239000 |
| Mar 31, 2018 | -$7.59 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 10, 2018 | $199000 |
| Dec 31, 2017 | -$0.81 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 16, 2018 | $100000 |
| Sep 30, 2017 | -$0.72 | N/A | N/A | N/A | N/A | -102.0% | N/A | N/A | Nov 9, 2017 | $130000 |
| Jun 30, 2017 | -$10.42 | N/A | N/A | N/A | N/A | -2075.7% | N/A | N/A | Aug 14, 2017 | $112000 |
| Mar 31, 2017 | -$10.18 | N/A | N/A | N/A | N/A | -1865.0% | N/A | N/A | May 11, 2017 | $137000 |
| Sep 30, 2016 | $35.99 | N/A | N/A | N/A | N/A | +6063.0% | N/A | N/A | Oct 17, 2016 | $117000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.29, after -$1.83 the year before. It was $2.27 for the year ended Dec 31, 2015, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.29 | N/A |
| Dec 31, 2024 | -$1.83 | N/A |
| Dec 31, 2023 | -$8.25 | N/A |
| Dec 31, 2022 | -$7.66 | N/A |
| Dec 31, 2021 | -$5.78 | N/A |
| Dec 31, 2020 | -$21.65 | N/A |
| Dec 31, 2019 | -$11.55 | N/A |
| Dec 31, 2018 | -$9.97 | -166.7% |
| Dec 31, 2017 | $14.96 | +560.3% |
| Dec 31, 2015 | $2.27 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,900 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 2,942 | 5 | |
| 2026Q2 | Jun 30, 2026 | 5,551 | 7 | |
| 2026Q1 | Mar 31, 2026 | 2,504 | 5 | |
| 2025Q4 | Dec 31, 2025 | 3,542 | 6 | |
| 2025Q3 | Sep 30, 2025 | 4,046 | 7 | |
| 2025Q2 | Jun 30, 2025 | 5,357 | 8 | |
| 2025Q1 | Mar 31, 2025 | 3,982 | 7 | |
| 2024Q3 | Sep 30, 2024 | 5,093 | 6 |
2026Q3 Earnings Call
Opening remarks
Miranda Benvenuti Investor Relations Thank you. Good afternoon, and thank you for participating in today's conference call. Joining me from BioCardia's leadership team are Peter Altman, President and Chief Executive Officer, and David McClung, the company's Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address BioCardia's expectations for future performance and operational results, and references to management's intentions, beliefs, projections, outlook, analyses, and current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products and technologies and obtaining regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors and cautionary statements described in BioCardia's report on Form 10-K filed with the SEC on March 24, 2026, and in our subsequently filed quarterly reports on Form 10-Q. The content of this call contains time-sensitive information that is accurate only as of today, November 12, 2026. Except as required by law, the company disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Dr. Peter Altman, BioCardia's President and CEO. Peter, please go ahead.
Peter Altman President and Chief Executive Officer Thank you, Miranda, and good afternoon to everyone on the call. The highlights of this third quarter have been the continued progress on the approval of CardiAMP cell therapy for the treatment of heart failure in Japan and the approval of our Helix transendocardial delivery catheter system in the United States. I would like to focus a little time on each of these regulatory initiatives to detail where we are, the risks, and our anticipated successful outcomes. Our efforts to seek approval in Japan for our CardiAMP cell therapy for the treatment of ischemic heart failure followed Japan's leadership in supporting these therapies, as it has recognized the potential for meaningful impact in treating heart failure. Japan has recently approved and reimbursed a cell therapy for patients with heart failure. Our CardiAMP cell therapy may have advantages over what has been approved in that it is autologous and requires no immunosuppression. Delivering a patient's own cells resonates with Japanese culture, which has historically avoided the transplantation of organs. Further, our CardiAMP cell therapy procedure is performed using minimally invasive catheter delivery, without the need to open the patient's chest surgically to deliver the cells. We expect to be able to discharge patients soon after the procedure, on the same day. The patient need is great, and we look forward to real-world assessment of CardiAMP cell therapy for these patients in Japan.
Frequently Asked Questions About BCDA
When is Biocardia's next earnings date?
Biocardia's next earnings report is expected for Mar 22, 2027.
Did BCDA beat earnings estimates last quarter?
Yes. Biocardia reported EPS of -$0.12 for the quarter ended Sep 30, 2026, above the -$0.15 estimate, a 20.00% surprise.
What EPS do analysts expect from BCDA next quarter?
The consensus EPS estimate for Biocardia for the quarter ending Dec 31, 2026 is -$0.16 from 4 analysts, with estimates from -$0.21 to -$0.12.
How often does BCDA beat earnings estimates?
Biocardia beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +17.75%.
BCDA pages: Overview, Earnings, Forecast, Financials, Competitors